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Lung cancer remains the leading cause of cancer-related
death worldwide. NSCLC accounts for more than 85% of
all lung cancers, and the prognosis for advanced-stage dis-
ease is typically poor. In recent years, the importance of
histologic subtypes of NSCLC has been recognized, and the
distinction between squamous and other NSCLC histologic
subtypes is now critical to patient management. Squamous
cell lung cancer (sqCLC) represents approximately 25% to
30% of NSCLC. The prognosis for patients with advanced
NSCLC is poorer for those with sqCLC than for those with
adenocarcinoma. This is partly due to a number of clinical
characteristics that distinguish sqCLC from other NSCLC
histologic subtypes, such as smoking history, comorbid
diseases, age, and molecular profile. Together, these factors
make sqCLC an especially challenging disease to manage.
Herein, we review some of the key clinicopathologic fea-
tures of sqCLC. Understanding these features to optimally
address many of the unique therapeutic challenges of this
disease is likely to be central to ultimately improving out-
comes for patients with squamous NSCLC.
 2016 International Association for the Study of Lung
Cancer. Published by Elsevier Inc. All rights reserved.
Keywords: NSCLC; Squamous cell lung cancer; Histologic
Subtype; Etiology
Introduction
Lung cancer remains the leading cause of cancer-
related death worldwide, accounting for 19.4% of
cancer-related deaths and 1.59 million deaths annually.1
Most patients present with locally advanced or meta-
static disease, as until recently there had been no
effective screening measures and metastases occur early
in the natural history of lung cancer. Consequently, the
prognosis for advanced-stage disease is poor, with an
overall 5-year survival rate of 17% in the United States.2
Tobacco consumption is well recognized as the major
risk factor for lung cancer, and because of the ongoing
tobacco epidemic in many parts of the world, the inci-
dence of lung cancer and related mortality is expected to
rise over the coming decades.1 As a result, lung cancer
will remain a considerable global burden and a major
focus of research.
NSCLC accounts for more than 85% of all lung can-
cers.2 In the past, advanced NSCLC was viewed as a
single disease entity and managed as such, with systemic
therapies the mainstay of treatment.3 More recently, the
subclassification of NSCLC into adenocarcinoma, large
cell carcinoma, and squamous cell carcinoma has gained
importance because of the therapeutic implications of
underlying histologic subtype.4,5 Several currently
available treatment options developed in the past decadefor NSCLC (e.g., bevacizumab, pemetrexed, and ninteda-
nib) are not approved or are not suitable for use in pa-
tients with the squamous histologic subtype owing to
toxicity and/or efficacy issues.6,7 Unfortunately, recent
improvements in patient outcomes have largely been
confined to patients with adenocarcinoma.6–9 Indeed, a
comparison of outcomes in recent clinical trials reveals
that the median survival of patients with an advanced
case of the squamous histologic subtype who are
receiving first-line therapy was approximately 30%
shorter than that of patients with other NSCLC sub-
types.10–14
In this context, this article reviews some of the key
characteristics of squamous cell lung cancer (sqCLC),
including pathologic features, clinical features, patient
characteristics, epidemiology, and molecular profile, to
bring into focus the specific challenges and opportunities
relating to this disease.Pathologic and Histologic Subtype
In the vastmajority of patients, advanced lung cancer is
diagnosed on the basis of small biopsy and cytologic
specimens rather than resection specimens; as a result,
the 2015 WHO classification of lung cancers provides
criteria for both scenarios. In the case of small biopsy and
cytologic samples, the main diagnostic categories are
adenocarcinoma, squamous cell carcinoma, and NSCLC
not otherwise specified (Table 1).15 The classification of
NSCLC according to small biopsy and cytologic samples in
the WHO guidelines is based closely on the 2011 Inter-
national Association for the Study of Lung Cancer, Amer-
ican Thoracic Society, and European Respiratory Society
classification.4 Given the importance of specific histologic
diagnosis in NSCLC because of its impact on subsequent
genetic testing and ultimately treatment, the classification
also aims to reduce the number of patients in whom
NSCLC not otherwise specified is diagnosed, not least by
the use of terminology in which one subtype is favored.
The microscopic features of sqCLC can help to
distinguish it from adenocarcinoma (Table 2). Squamous
cell carcinoma is characterized histologically by areas of
keratinization and the presence of intercellular bridges,
whereas adenocarcinoma typically shows gland forma-
tion and papillary structures on histologic examina-
tion.9,16 The presence of morphological components of
both adenocarcinoma and sqCLC histologic subtypes,
with each representing at least 10% of the tumor cells,
could mean adenosquamous carcinoma.15
In addition to morphological examination, immuno-
histochemical analysis can be used to help identify the
histologic subtype. Thyroid transcription factor-1, p63,
and p40 are the principal markers used currently for
subtyping NSCLC: thyroid transcription factor-1 as a
Table 1. 2015 WHO Classification of NSCLC for Small Biopsy and Cytologic Specimens
Terminology Morphologic Pattern and Staining
Adenocarcinoma
Adenocarcinoma with lepidic pattern Adenocarcinoma morphologic patterns clearly present
Invasive mucinous adenocarcinoma
Adenocarcinoma with colloid features
Adenocarcinoma with fetal features
Adenocarcinoma with enteric features
NSCLC, favor adenocarcinoma Morphologic patterns not present, but staining supports adenocarcinoma
(e.g., thyroid transcription factor-1)
Squamous cell carcinoma Squamous cell morphologic patterns clearly present
NSCLC, favor squamous cell carcinoma Morphologic patterns not present, but staining supports squamous cell carcinoma
(e.g., p40)
NSCLC, not otherwise specified No clear adenocarcinoma or squamous morphologic patterns or staining pattern
Squamous cell and adenocarcinoma morphologic patterns present (adenosquamous)
Note: This table relates to diagnoses made on the basis of small biopsy and cytologic samples.
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markers for sqCLC.17 Studies have shown that p63 has
an extremely high sensitivity for sqCLC18; however, a
main limitation of p63 is low specificity owing to its
reactivity in adenocarcinoma, as well as in other tumor
types, particularly lymphomas.19 p40 is a relatively new
predictive marker for sqCLC that has demonstrated
sensitivity comparable to that of p63 but superior
specificity.20 Cytokeratin 5/6 may also be a useful
marker for sqCLC, particularly in cases of poorly differ-
entiated or undifferentiated NSCLC.21 Adenosquamous
carcinoma may also be diagnosed if some populations of
cells immunostain for thyroid transcription factor-1 and
others immunostain for squamous markers described
later in this article.15 It should be noted that in some
cases, it may be difficult to distinguish metastatic squa-
mous cell cancer originating in a distant site from a true
primary sqCLC solely on the basis of immunohisto-
chemical analysis or microscopy.22
Clinical Features
NSCLC histologic subtype correlates with the site of
origin. SqCLC is usually centrally located, typicallyTable 2. Key Cellular Characteristics of Squamous NSCLC and
Characteristics Squamous Cell Lung Cancer
Cell arrangements Cells appear in cohesive aggregates, usually
sheets, and may appear as irregular shap
(e.g., spindle-shaped and tadpole-shaped
Cytoplasmic features Abundant cytoplasm in irregularly shaped ce
Nuclear features Central, irregular hyperchromatic nuclei, ex
one or more small nucleolibeginning in early versions of flat cells that line the in-
side of the lung airways and arising in the proximal
bronchi. Conversely, adenocarcinoma is usually located
peripherally and related to surface alveolar epithelium
or bronchial mucosal glands.9,23
As a consequence of its central location, sqCLC is
more likely to invade larger blood vessels and vital
structures in the mediastinum and is more likely to
cause bronchial obstruction.9,23 Furthermore, cases of
peripherally located sqCLC usually present once the tu-
mor has grown larger and invaded the chest wall. In
addition, the squamous histologic subtype is associated
with tumor cavitation, with more than 80% of cavitating
tumors identified as sqCLC.24,25 It is also noteworthy
that, on average, sqCLC tumors grow more quickly
than adenocarcinoma tumors: in a study of 63 patients
with NSCLC in the United States, the median doubling
time was 160 days for sqCLC compared with 387 days
for adenocarcinoma/broncheoalveolar carcinoma
(p ¼ 0.0031).26
These clinical features, particularly cavitation, may
explain why patients with sqCLC are at increased risk for
potentially fatal pulmonary hemorrhage compared withAdenocarcinoma
Adenocarcinoma
in flat
es
cells)
Single cells or arranged in three-dimensional clusters;
borders of cell clusters may be sharply defined
lls Relatively abundant cytoplasm, typically more
translucent than squamous cell carcinoma.
Cytoplasm can range from distinctly homogeneous
to granular to foamy because of the presence of
vacuoles
hibiting Single, eccentric, and round to oval with relatively
smooth contours and minimal nuclear irregularity.
Chromatin tends to be finely granular and evenly
dispersed
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cohort of patients who had died because of lung cancer
(n ¼ 100), pulmonary hemorrhage was significantly
correlated with sqCLC, with 50% (six of 12) of those who
died as a direct result of pulmonary hemorrhage having
sqCLC.25 In a retrospective study of 583 patients with
advanced NSCLC, all patients who had baseline cavita-
tion (n ¼ 38) and who experienced a fatal pulmonary
hemorrhage (n ¼ 3) had sqCLC.27 In the same study,
multivariate analysis found baseline major cavitation
(OR ¼ 17.9) and the squamous histologic subtype (OR ¼
5.5) to be significant independent risk factors for fatal
pulmonary hemorrhage.27
Etiology
Tobacco smoking is the underlying cause of more
than 80% of all lung cancers and is the major risk factor
for sqCLC, as well as other NSCLC subtypes.28 Impor-
tantly, smoking cessation can substantially reduce the
risk for development of lung cancer. In a population-
based study, there was an inverse relationship between
the risk for development of lung cancer and the time
since smoking cessation, with a cumulative risk for death
due to lung cancer by age 75 years of 15.9% for men
who continued to smoke cigarettes, compared with
9.9%, 6.0%, 3.0%, and 1.7% for those who stopped at
age 60, 50, 40, and 30 years, respectively.29 Smoking
cessation is also an important goal in patients in whom
lung cancer has already been diagnosed, as it is associ-
ated with increased efficacy of treatments and improved
quality of life.30–33 In a meta-analysis, overall mortality
in active smokers after surgery for stage I to stage IIIA
NSCLC was 2.94 times higher than in nonsmokers.33 In a
retrospective study of patients with stage I or II NSCLC,
active smokers had a 2-year survival rate of 41% after
radiotherapy compared with 56% for patients who had
ceased smoking or who had never smoked.31 Smoking
has also been reported as a negative predictor ofFigure 1. Relative risk for lung cancer based on smoking status i
Pesch et al.35 Copyright ª 2012 John Wiley & Sons, Inc. All Rigresponse to chemotherapy in patients with advanced
lung cancer and can also affect the efficacy of targeted
therapy in this setting.30,32 Hence, not only is smoking
central to lung cancer development but smoking cessa-
tion is also critical to disease prevention and improved
outcomes.
Active tobacco smoking has a stronger association
with squamous disease than with adenocarcinoma.34,35
In a large pooled analysis of case-control studies
(13,169 patient cases), the ORs for squamous NSCLC in
current or former smokers versus in those who had
never smoked were 45.6 and 14.7, respectively,
compared with 10.8 and 4.2 for adenocarcinoma
(Fig. 1).35 In addition, in a population-based study of
20,561 patients in Poland in whom lung cancer was
diagnosed between 1995 and 1998, the patients with
adenocarcinoma smoked less intensely than the patients
with squamous NSCLC: 31 versus 36 packs per year in
women and 38 versus 42 packs per year in men.36
In addition to the etiologic association with lung
cancer, smoking has been formally established as a
causative link to 21 diseases, including chronic
obstructive pulmonary disease and cardiovascular dis-
ease. Moreover, pooled data from five cohort studies
(n ¼ 954,029 patients age 55 years) recently showed
that a significant portion of excess mortality among
smokers was due to causes not previously recognized as
being related to smoking, such as renal failure, hyper-
tensive heart disease, and intestinal ischemia.37 The
additional potential disease burden due to smoking is a
contributor to poor outcomes in patients with sqCLC, as
well as in patients with other histologic subtypes of lung
cancer, and emphasizes the importance of cessation.
Smoking is declining in many Western countries but
is currently peaking in other parts of the world, such as
China, Eastern Europe, and several countries in Af-
rica.38,39 At present, the highest incidence rates of lung
cancer are still seen in North America and northernn men. CI, confidence interval. Adapted with permission from
hts Reserved.
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high; however, the geographic distribution of lung cancer
cases is expected to change, reflecting trends in tobacco
consumption.
Given the prominent role of smoking in lung cancer,
screening of at-risk populations has long been suggested.
The National Lung Screening Trial, which was launched
in 2002, found that annual screening using low-dose
helical computed tomography scans of individuals with
a 30–pack-year or longer history of cigarette smoking
(or smoking cessation 15 years if a former smoker)
was associated with a 20% relative reduction in lung
cancer mortality.40 Screening of individuals age 55 to 80
years who meet this criterion is now recommended by
the U.S. Preventive Services Task Force.41 In the National
Lung Screening Trial, adenocarcinoma was the most
common histologic subtype detected by low-dose helical
computed tomography (39.9%), with 21.1% of detected
tumors being sqCLC.40 A post hoc analysis of this trial
reported that the survival benefit of low-dose helical
computed tomography versus chest radiography
observed for adenocarcinoma was not observed for
sqCLC (mortality risk ratio ¼ 0.75, 95% confidence in-
terval: 0.60–0.94 for adenocarcinoma versus 1.23, 95%
confidence interval: 0.92–1.64 for sqCLC).42 Screening
trials are ongoing in many parts of the world to further
evaluate the benefits, harm, and cost-effectiveness of
lung cancer screening.43,44Epidemiology
In recent decades, the predominant NSCLC histologic
type has shifted from sqCLC to adenocarcinoma, espe-
cially in developed countries.45 This may be due in part
to the shift to low-tar filter cigarettes, in which small
particles are inhaled more deeply into the periphery of
the lung.46 Importantly, however, sqCLC still accounts
for 25% to 30% of lung cancers,47 thereby representing
approximately half a million cases in 2012.1
Although the histologic distribution of NSCLC differs
geographically, in relative terms sqCLC is more common
in men. On the basis of a review of international sources
of cases diagnosed between 1998 and 2002, sqCLC
accounted for 27% to 46% of NSCLC cases in men,
compared with 11% to 23% in women.38 Indeed, ac-
cording to these data, in a number of countries including
the United Kingdom, sqCLC was the most common
NSCLC histologic subtype in men (Fig. 2).38 In contrast,
adenocarcinoma is more than twice as common as any
other histologic subtype of lung cancer in women.47
Male sex has been established as a negative prog-
nostic factor for NSCLC, as survival rates for women have
been shown to be significantly better than those for
men.48 In a cohort study of 4618 patients in whomNSCLC was diagnosed between 1997 and 2002 in the
United States, the 1- and 5-year survival rates in women
were 60% and 19%, respectively, compared with 51%
and 15% in men, respectively.49
NSCLC, including sqCLC, is associated with increased
age. The median age at diagnosis for patients in the
United States with lung cancer diagnosed between 2008
and 2012 was 70 years.50 Patients with sqCLC tend to be
slightly older than those with adenocarcinoma. In the
Surveillance, Epidemiology, and End Results Registry of
more than 50,000 patients with advanced NSCLC diag-
nosed between 1988 and 2003, the mean age of patients
with sqCLC was 66.9 years compared with 64.2 years for
patients with adenocarcinoma, and 62% of patients with
sqCLC were 65 years or older at diagnosis, compared
with 51% for adenocarcinoma.8 Increased age is asso-
ciated with worse outcomes in NSCLC; in the Surveil-
lance, Epidemiology, and End Results Registry of
patients in the United States in whom NSCLC (of any
stage) was diagnosed between 2004 and 2010, those
younger than 65 years had a 5-year survival rate of 23%,
compared with 19% for those older than 65 years and
17% for those older than 75 years.51 In the same reg-
istry, patients older than 65 years were less likely to
receive care in line with current guidelines,52 a finding
supported by the Netherlands Cancer Registry, in which
the proportion of patients with stage IV NSCLC receiving
chemotherapy decreased with increasing age, from 60%
in patients younger than 65 years to 19% in those age 75
years or older.53Comorbidities
As sqCLC is associated with increased age and has a
stronger association with smoking, it is not surprising that
patients with squamous disease have a high degree of
smoking- andage-related comorbidities andahigher rateof
comorbidity than patients with other lung cancers.54,55 In
one large population-based study, 64%of patientswith the
squamous histologic subtype had a concomitant disease,
compared with 52% of patients with other histologic sub-
types (p¼0.001).55 Inparticular, patientswith sqCLChada
higher incidence of chronic obstructive pulmonary disease
and cardiovascular disease.54,55
As for most cancers, the presence of comorbid condi-
tions in NSCLC is associated with a worse prognosis.55–57
Comorbidity influences survival by affecting treatment
choice and treatment adherence, as well as by direct
comorbidity-related deaths. In addition, comorbidity in
elderly patientswith lung cancer has been associatedwith
increased cancer-specific mortality.57 In a study of 1255
patientswithNSCLC,aCharlsoncomorbidity indexscoreof
1 or higher was associated with significantly shorter sur-
vival,56 and in a further study, severe comorbidity
AB
Figure 2. Distribution of lung cancer by histologic type in (A) women and (B) men, 1998–2002. US, United States; UK, United
Kingdom; sqCLC, squamous cell lung cancer. Adapted with permission from Youlden et al.38
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with increasedmortality.57 Indirect estimates suggest that
mortality rates for patients with sqCLC who have smoked
are 11 times higher than those of patients who have never
smoked,58whichmaypartly reflect theburdenof smoking-
related comorbid conditions.
Certain comorbidities, such as lung, cardiovascular,
and renal disease, may influence treatment selection,
and in clinical practice patients with cancer and
comorbidities may be less likely to receive aggressive, or
any, chemotherapy.59 In line with this, in a population-
based study of 5428 patients with advanced NSCLC
diagnosed between 2001 and 2012, patients with sqCLC
were less likely to receive chemotherapy than were
those with adenocarcinoma (38% versus 52% [p <
0.001]).53 This may reflect the clinical features of sqCLC
already discussed, as well as the high incidence of
comorbidities in patients with sqCLC, thereby making
these patients less suitable for chemotherapy.
Comorbidity also affects toxicity of chemotherapy. In
one study of 402 patients with lung cancer, those withsevere comorbidity were more likely to experience
thrombocytopenia (46% versus 36%), febrile neutropenia
(12% versus 5%), or death caused by neutropenic infec-
tion (3% versus 0%) after chemotherapy.55,59
Thus, the potential impact of comorbidity on prog-
nosis in sqCLC is multifactorial, and the high burden of
comorbidity observed in sqCLC likely contributes to the
challenging nature of disease management.
Molecular Biology
Important differences between sqCLC and other
NSCLC histologic subtypes also exist with regard to the
tumor genetic profile. In recent years, identification of
EGFR mutations and anaplastic lymphoma kinase gene
ALK rearrangements as oncogenic drivers has led to
major therapeutic advances for the subset of patients
with NSCLC with these alterations.60–62 However, the
incidence of EGFR mutations and ALK gene rearrange-
ments in sqCLC is low (approximately 2.7% and
1.5–2.5%, respectively),63–65 and therefore only a few
patients with SqCLC are candidates for either EGFR
September 2016 Clinicopathologic Features of Squamous NSCLC 1417tyrosine kinase inhibitors (TKIs) or ALK inhibitors. Some
studies have suggested that squamous tumors may not
harbor EGFR mutations at all, and that the low frequency
reported is due to samples of mixed histologic subtypes
(e.g., adenosquamous) being diagnosed as the squamous
subtype.66 Hence, the benefits of EGFR TKIs and ALK
inhibitors have largely been confined to patients with a
nonsquamous histologic subtype.67,68
Despite a dearth of EGFR mutations or ALK gene
rearrangements, sqCLC is characterized by a high overall
mutation rate and marked genomic complexity.69 The
Cancer Genome Atlas analyzed tumor samples from
178 patients with previously untreated stage I to IV sqCLC
and reported that 96% of samples harbored molecular
abnormalities, including alterations in fibroblast
growth factor receptor gene (FGFR), phosphatidylinositol
3-kinase gene (PI3K), EGFR, and phosphatase and tensin
homolog gene (PTEN) (Fig. 3).69 A further cancer cohort
study also found that sqCLC is characterized by a high
mutational burden, with an average of 261 somatic mu-
tations per tumor, and a mutational spectrum showing a
signature of exposure to cigarette smoke.70 Interestingly,
in the same study, comparative analysis between sqCLC
samples from Korean and North American patients
demonstrated a similar spectrum of alterations in these
two populations, which contrasts with lung adenocarci-
noma, in which the frequency of genomic alterations in
oncogenes was shown to differ among ethnic groups.70
The Cancer Genome Atlas study identified two sam-
ples with an EGFR mutation (1%), although neither of
these involved either of the two mutations most
commonly seen in adenocarcinoma (exon 21 L858RFigure 3. Estimated frequency of genetic alterations in squamo
Cancer Genome Atlas study. Alterations were defined as somat
fications, or significant upregulation or downregulation of gene
gene; FGFR2, FGFR2 fibroblast growth factor receptor 2 gene
PIK3CA, phosphatidylinositol-4,5-bisphosphate 3-kinase catalyti
GRAF, GRAF Rho GTPase activating protein 26 gene; AKT3, AKT/
the Cancer Genome Atlas Research Network.69 Copyright ª 2012point mutation or exon 19 deletions). However, 9% of
samples had an EGFR alteration of some kind,69 a fre-
quency supported by other studies that found EGFR
amplification in 7% to 11% of sqCLC cases.69,71 In fact,
high EGFR gene copy numbers and protein over-
expression have been observed more frequently in
squamous disease than in adenocarcinoma (82% versus
44%), and an association between increased gene copy
number and poor prognosis has been observed.71 In
addition, EGFR gene and protein overexpression have
been explored as potential predictive biomarkers of
response to EGFR monoclonal antibodies.72,73 EGFR
protein expression and gene copy number are both
continuous variables and are measured by immunohis-
tochemical analysis and fluorescence in situ hybridiza-
tion, respectively. The method used and the cutoff for
delineating positive from negative may affect predictive
biomarker validity.73–75 Furthermore, the cut point for
detection from background or for a prognostic role may
differ from the predictive cut point.72,74
Alterations in fibroblast growth factor receptor 1 gene
(FGFR1) were seen in 7% of samples in The Cancer
Genome Atlas study,69 although FGFR1 amplification rates
of 16% to 21% have been reported in other cohorts of
squamous cell tumors.76,77 Notably, a lower frequency of
3.4% has been observed in adenocarcinoma.76 However,
as with EGFR, the cutoff that defines FGFR-positive and
FGFR-negative varies between studies. In one study of 203
NSCLC cases, a 3.5-fold amplification optimally divided
patients into groups with different survival rates. Using
the 3.5-fold cutoff, the FGFR1 amplification rate was
approximately 5% in sqCLC and approximately 4% inus cell lung cancer based on analysis of 178 samples from The
ic mutations, homozygous deletions, high-level focal ampli-
expression. FGFR1, FGFR1 fibroblast growth factor receptor 1
; FGFR3, FGFR3 fibroblast growth factor receptor 3 gene;
c subunit alpha gene; PTEN, phosphatase and tensin homolog;
serine threonine kinase 3 gene. Adaptedwith permission from
International Association for the Study of Lung Cancer.
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been or continue to be evaluated for sqCLC. Initial prom-
ising preclinical data have suggested that FGFR1 inhibition
may be an encouraging approach for the subset of squa-
mous tumors harboring an FGFR1 amplification.76,79,80
However, clinical response rates have been disappoint-
ingly low.81,82 Recently, evidence has been presented that
FGFR1 mRNA and protein expression, rather than gene
copy number, may predict sensitivity to FGFR TKIs across
all lung cancer histologic subtypes.83
Alterations in the PI3K pathway are common in
sqCLC, with alterations in one of the three major com-
ponents of the pathway (phosphatidylinositol-4,5-
bisphosphate 3-kinase catalytic subunit alpha gene
[PIK3CA], PTEN, or AKT/serine threonine kinase 3 gene
[AKT3]) observed in 47% of squamous tumors.69 PIK3CA
alterations were identified in 16% of samples in The
Cancer Genome Atlas cohort. PIK3CA alterations also
appear to occur more commonly in sqCLC, with one
study finding copy number gains in 42.9% of squamous
tumors compared with in 9.5% of adenocarcinomas.84
PTEN mutations also appear to be more common in
squamous cell carcinoma than in adenocarcinoma.85 Of
note, a recent phase II study of the pan-PI3K inhibitor
buparlisib in relapsed PI3K pathway–activated NSCLC
was stopped after failing to meet its primary objective
during stage 1 of the study.86
Alterations in other genes such as discoidin domain-
containing receptor 2 gene (DDR2) and nuclear factor
erythroid-2-related factor 2 gene (NRF2) have been re-
ported in up to 3.8% and 11% of sqCLC, respectively,
and may potentially represent therapeutic targets.85,87
However, a range of DDR2 mutations, not all of which
have been definitely proved to be oncogenic, have been
identified.87,88 To date, clinical trials of agents targeting
DDR2 have been hampered by excessive toxicity, espe-
cially in patients with sqCLC.89 Lack of efficacy has also
been noted.90 Preclinical studies show that mutant NRF2
is oncogenic and targetable through inhibition of
mammalian target of rapamycin.91
Together, the frequent genetic alterations in sqCLC
tumors suggest common dysfunction in cell cycle con-
trol, response to oxidative stress, apoptotic signaling,
and/or squamous cell differentiation.69 Continued focus
on this area will be vital to ultimately facilitating a
personalized therapeutic approach for sqCLC on par
with that seen currently in adenocarcinoma. The Squa-
mous Lung Cancer Consortium is currently studying
prognostic classifiers in sqCLC as part of a U.S. National
Cancer Institute–initiated collaboration (the Strategic
Partnering to Evaluate Cancer Signatures program). The
study includes molecular profiling of a large number of
sqCLC cases (600–800) and has an additional goal of
identifying new potential therapeutic targets for sqCLC.Immunological Profile
In addition to molecular aberrations, there are also
immunological differences between squamous and non-
squamous histologic subtypes. Squamous tumors more
frequently express certain tumor antigens, such as
melanoma-associated antigen [MAGE]-A3 and MAGE-
A4.92 Of note, however, in the MAGRIT phase III trial of
patients with NSCLC, adjuvant treatment with MAGE-A3
cancer immunotherapy did not increase disease-free
survival compared with placebo.93 Squamous tumors
also exhibit more extensive infiltration of CD8þ effector
cells, and less extensive infiltration of regulatory T cells,
compared with nonsquamous tumors.94,95 In a study of
65 patients with NSCLC, squamous tumors were asso-
ciated with a prominent adaptive immune response,
whereas greater innate immune responses were
observed in adenocarcinomas and large cell carci-
nomas.96 Much recent attention has also been paid to
immune checkpoint proteins, in particular the pro-
grammed death-1 receptor and its ligand programmed
death ligand-1 (PD-L1). Initial studies indicate that PD-
L1 is expressed in 25% to 39% of NSCLC tumors,97,98
although the role of PD-L1 expression as a biomarker
is yet to be fully determined. The use of multiple assays
with widely varying frequencies of positivity has
complicated the interpretation of these data.99–101 Pre-
liminary evidence also suggests that smoking history and
a greater mutational burden may correlate with height-
ened response to anti–PD-L1 agents,99,102 characteristics
that are more often associated with sqCLC. The recent
second-line approvals of nivolumab and pembrolizumab
across NSCLC histologic subtypes, including squamous
cancer, illustrate the new potential of immunotherapy in
squamous lung cancer.103,104 Several anti–programmed
death-1 and anti–PD-L1 agents are now in first-line
phase III clinical development compared with standard
platinum doublets as either monotherapy in PD-L1–
enriched populations or in combination with chemo-
therapy in nonenriched populations.105–108 The potential
influence of differences in the immune environment
between sqCLC and other histologic subtypes may be
relevant for new and emerging immunotherapies,
although this is yet to be fully established.95Commentary
SqCLC is an especially challenging disease and is
associated with a worse prognosis than other histologic
subtypes of NSCLC. This is partly due to the aforemen-
tioned characteristics, including tumor location, high rate
of comorbidity, and genetic complexity of the disease. As a
consequence, several recent treatments for NSCLC,
including novel drugs targeting oncogenic drivers, new
chemotherapeutic agents, and antiangiogenic therapies,
September 2016 Clinicopathologic Features of Squamous NSCLC 1419have all demonstrated limitations in terms of efficacy and/
or safety in sqCLC.68,109,110 Therefore, the recommenda-
tions for first-line treatment in the vast majority of pa-
tients with sqCLC are the same as a decade ago (i.e.,
platinum-doublet chemotherapy).
It is clear that efforts are needed to address this
problem, and one of the main strategies to do so is to
improve the understanding of oncogenic drivers specific
to the squamous histologic subtype. Genetic profiling of
squamous tumors may prove central in discovering
novel drug targets and developing new treatments that,
together with increased appreciation of the clinical
characteristics of sqCLC, will ultimately result in
improved patient outcomes.67 Further investigation of
predictive biomarkers for response to immunotherapies
will also be crucial.Acknowledgments
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